Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 9606985, 7 pages
https://doi.org/10.1155/2017/9606985
Research Article

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

1Division of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China
2Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China
3Department of Endocrinology, Kunshan Rehabilitation Hospital, Suzhou, Jiangsu 215314, China
4Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
5Shanghai Pituitary Tumor Center, Shanghai 200040, China
6Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China
7Department of Endocrinology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, China

Correspondence should be addressed to Zhaoyun Zhang; nc.ude.naduf@gnahznuyoahz

Received 28 November 2016; Accepted 23 January 2017; Published 15 March 2017

Academic Editor: Andrea G. Lania

Copyright © 2017 Wenjuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Guinto, M. Abdo, E. Zepeda, N. Arechiga, and M. Mercado, “Acromegaly: role of surgery in the therapeutic armamentarium,” International Journal of Endocrinology, vol. 2012, Article ID 306094, p. 13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Carlsen, J. Svartberg, T. Schreiner et al., “Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure,” Clinical Endocrinology, vol. 74, no. 6, pp. 736–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Mercado, F. Borges, H. Bouterfa et al., “A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly,” Clinical Endocrinology, vol. 66, no. 6, pp. 859–868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ben-Shlomo and S. Melmed, “Somatostatin agonists for treatment of acromegaly,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. 192–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Colao, R. S. Auriemma, and R. Pivonello, “The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly,” Pituitary, vol. 19, no. 2, pp. 210–221, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Legovini, E. De Menis, D. Billeci, B. Conti, P. Zoli, and N. Conte, “111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients,” Journal of Endocrinological Investigation, vol. 20, no. 7, pp. 424–428, 1997. View at Publisher · View at Google Scholar
  7. M. R. Gadelha, L. Kasuki, and M. Korbonits, “Novel pathway for somatostatin analogs in patients with acromegaly,” Trends in Endocrinology and Metabolism, vol. 24, no. 5, pp. 238–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Sheppard, M. D. Bronstein, P. Freda et al., “Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study,” Pituitary, vol. 18, no. 3, pp. 385–394, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. L. E. Wildemberg, L. V. Neto, D. F. Costa et al., “Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs,” Journal of Endocrinological Investigation, vol. 36, no. 1, pp. 38–43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Wang, M. Shen, W. He et al., “The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly,” Endocrine Journal, vol. 63, no. 9, pp. 819–834, 2016. View at Publisher · View at Google Scholar
  11. E. Verrua, E. Ferrante, M. Filopanti et al., “Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease,” International Journal of Endocrinology, vol. 2014, Article ID 581594, p. 8, 2014. View at Publisher · View at Google Scholar
  12. T. R. Bandgar, V. Sarathi, V. Shivane, N. Bansode, P. S. Menon, and N. S. Shah, “The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly,” Journal of Postgraduate Medicine, vol. 56, no. 1, pp. 7–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. U. Freda, L. Katznelson, A. J. van der Lely, C. M. Reyes, S. Zhao, and D. Rabinowitz, “Long-acting somatostatin analog therapy of acromegaly: a meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4465–4473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. F. Taboada, R. M. Luque, L. V. Neto et al., “Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR,” European Journal of Endocrinology, vol. 158, no. 3, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Casar-Borota, A. Heck, S. Schulz et al., “Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11, pp. E1730–E1739, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Heck, K. E. Emblem, O. Casar-Borota, J. Bollerslev, and G. Ringstad, “Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly,” Endocrine, vol. 52, no. 2, pp. 333–343, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Caron, J. S. Bevan, S. Petersenn et al., “Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 4, pp. 1282–1290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Lugo, L. Pena, and F. Cordido, “Clinical manifestations and diagnosis of acromegaly,” International Journal of Endocrinology, vol. 2012, Article ID 540398, p. 10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Melmed, “Acromegaly pathogenesis and treatment,” The Journal of Clinical Investigation, vol. 119, no. 11, pp. 3189–3202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ferone, W. W. de Herder, R. Pivonello et al., “Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1412–1417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. L. E. Wildemberg, L. Vieira Neto, D. F. Costa et al., “Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry,” Journal of Endocrinological Investigation, vol. 35, no. 6, pp. 580–584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. L. Fougner, O. C. Borota, J. P. Berg, J. K. Hald, J. Ramm-Pettersen, and J. Bollerslev, “The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma,” Clinical Endocrinology, vol. 68, no. 3, pp. 458–465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. V. Neto, O. Machado Ede, R. M. Luque et al., “Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 1931–1937, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Plockinger, S. Albrecht, C. Mawrin et al., “Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1203–1210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Lesche, D. Lehmann, F. Nagel, H. A. Schmid, and S. Schulz, “Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 654–661, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Cescato, S. Schulz, B. Waser et al., “Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists,” The Journal of Nuclear Medicine, vol. 47, no. 3, pp. 502–511, 2006. View at Google Scholar
  27. A. Colao, R. S. Auriemma, G. Lombardi, and R. Pivonello, “Resistance to somatostatin analogs in acromegaly,” Endocrine Reviews, vol. 32, no. 2, pp. 247–271, 2011. View at Publisher · View at Google Scholar · View at Scopus